GT Biopharma, Inc. Company Review & Valuation

OTC Markets
Latest Price

About GT Biopharma, Inc.

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based off its proprietary technology platforms.

The company develops immuno-oncology product candidates, including OXS-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors; OXS-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate targeting CD33+ malignancies; OXS-C3550, a next-generation version of OXS-3550 containing a modified CD16 component; and OXS-1615, a single-chain fusion protein that targets epithelial tumors and CD133 positive solid tumors.

It also develops central nervous system central nervous system, such as GTP-004, a fixed-dose combination tablet that has completed Phase I clinical trial for the treatment of the muscle weakness associated with myasthenia gravis; PainBrake, a patented formulation of carbamazepine to treat neuropathic pain; and GTP-011, a transdermal product for the prevention of motion sickness.

GT Biopharma, Inc.

has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a novel 161533 TriKE fusion protein for cancer therapies.

The company was formerly known as OXIS International, Inc.

and changed its name to GT Biopharma, Inc.

in July 2017.

GT Biopharma, Inc.

was founded in 1965 and is based in Washington, District of Columbia.

HQ Location
Washington, District of Columbia

Stock Price

Price data not available for GT Biopharma, Inc..


Please login or create a free account to view the contents of this section.

Financial Reports

Please login or create a free account to view the contents of this section.

Similar Companies

back to top

Valuu provides insights and tools for self-directed stock investors. It enables you to easily find, valuate and track your stock investments with the help of reliable financial data and transparent analysis tools.

Disclaimer: This website is a data portal, which aggregates information about public companies. It is not a stock broker and does not give advice concerning specific investment decisions or tax or legal advice. All data is provided "as-is" with no guarantee for correctness and/or completeness. All company names, logos, and brands are intellectual property of their respective owners. The use of them is for editorial purposes only and does not imply any affiliation or endorsement.
© 2019-2022 Valuu Analytics Sàrl